Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - raul+sakoda
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells
Abstract: Hematopoietic and pluripotent stem cells can be differentiated into T cells with potential clinical utility. Current approaches for in vitro T cell production rely on Notch signaling and artificial mimicry of thymic selection. However, these approaches result in unconventional or phenotypically aberrant T cells; which may lead to unpredictable...
Published: 4/8/2024
|
Inventor(s):
Raul Sakoda
,
Nicholas Klemen
,
Nicholas Restifo
Keywords(s):
DIFFERENTIATION
,
Induced Pluripotent Stem Cells
,
IPSCS
,
RESEARCH MATERIAL
,
Restifo
,
T Cells
,
Thymic Environment
,
Tool
Category(s):
TherapeuticArea > Infectious Disease
,
Application > Therapeutics
,
TherapeuticArea > Oncology
,
Collaboration Sought > Licensing
Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use
Abstract: Hematopoietic progenitor cells (HPC) are multi-potent hematopoietic lineage cells that can differentiate into any type of blood cell, including but not limited to erythrocytes, T cells, B cells, and natural killer cells. As such, they have high therapeutic potential in the fields of regenerative medicine and cancer immunotherapy, especially...
Published: 4/8/2024
|
Inventor(s):
Raul Sakoda
,
Nicholas Restifo
,
Meghan Good
,
Naritaka Tamaoki
Keywords(s):
3D Culture
,
BIOREACTOR
,
Hematopoietic Progenitor Cells
,
hiPSC
,
hMSC
,
HPC
,
Human Mesenchymal Stem Cells
,
Immunotherapy
,
Induced Pluripotent Stem Cells
,
iPSC
,
Vizcardo
Category(s):
TherapeuticArea > Immunology
,
TherapeuticArea > Oncology
,
Application > Therapeutics
,
Collaboration Sought > Licensing
High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes
Abstract: One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers...
Published: 4/8/2024
|
Inventor(s):
Raul Sakoda
,
S M Rafiqul Islam
,
Naritaka Tamaoki
,
Takuya Maeda
,
Nicholas Restifo
Keywords(s):
act
,
adoptive cell therapy
,
ANTIGEN-SPECIFIC
,
Cancer Targets
,
Immunotherapy
,
Induced Pluripotent Stem Cells
,
iPSC
,
Restifo
,
Rosenberg
,
T Cell Receptors
,
TCR
,
TIL
,
Tumor Infiltrated Lymphocytes
Category(s):
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Application > Therapeutics
,
Collaboration Sought > Licensing
In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells
Abstract: The thymus is an integral part of the adaptive immune system as it generates T cells. Its function diminishes rapidly as the body ages, leading to a compromise of the immune system in the elderly. Reconstitution of adaptive immunity through mass production of different T cell types is therefore a therapeutic need in immunocompromised populations....
Published: 4/8/2024
|
Inventor(s):
Raul Sakoda
,
Nicholas Restifo
Keywords(s):
Aging
,
IMMUNOCOMPROMISED
,
Immunotherapy
,
Natural Killer T Cells
,
NKT
,
Organogenesis
,
Organoid
,
Pluripotent Stem Cells
,
T Cells
,
THYMUS
,
Vizcardo
Category(s):
Application > Therapeutics
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Collaboration Sought > Licensing